UK and US Reach New Agreement to Keep Drug Tariffs at Zero
UK and US Reach New Agreement to Keep Drug Tariffs at Zero
The United Kingdom and the United States have reached a significant trade agreement aimed at reducing cost pressures in pharmaceutical commerce and supporting mutual growth objectives. Under the agreement, the US will continue to maintain zero tariffs on pharmaceutical exports from the UK; in return, the UK has committed to raising payments to drug manufacturers through its national healthcare system, the NHS – National Health Service. This decision comes after protracted price-setting discussions between the two nations.
According to information reported by BBC News, the UK has agreed to increase NHS payment levels for newly developed medicines by 25 percent. This increase effectively responds to claims put forward by the Trump administration that "the US unfairly bears the burden of international drug pricing." The Trump administration had contended that elevated prescription drug prices in the US are partly attributable to other nations' supplies of lower-priced pharmaceuticals.
Another critical component of the agreement is an expansion of the NHS's total pharmaceutical spending. Currently, drug expenditure comprises approximately 0.3 percent of UK GDP. Under the new arrangement, the UK has committed to increasing this share to 0.6 percent of GDP over the next ten years. This change represents a significant expansion in NHS budgets and promises faster access to next-generation medicines.
This development follows US President Donald Trump's threat in recent months to impose 100 percent tariffs on UK branded drug imports. Trump's statements had created tensions in US-UK pharmaceutical trade, bringing into focus the mutual interdependencies between the two nations' drug sectors. The new agreement demonstrates a rebalancing of relations in the wake of this threat.
Commenting on the agreement via social media platform X, UK Secretary of State for Science, Innovation and Technology Liz Kendall said the arrangement would be beneficial for both British patients and pharmaceutical companies. Kendall noted that "Patients will get cutting-edge medicines sooner, while innovative firms will be able to grow and thrive," underscoring the agreement's two-sided benefits.
The pharmaceutical sector is a critical export item for the UK economy. During the September 2024 – September 2025 period, UK pharmaceutical exports to the US reached 11.1 billion GBP (14.6 billion USD). This figure represents more than 17 percent of the country's total merchandise exports during the same period. Consequently, maintaining zero tariffs carries significant economic importance for the UK.
According to specialists, the agreement will provide stability for British manufacturers in the US pharmaceutical market while reinforcing the UK's need to increase research and development investment. Rising NHS payment capacity may incentivize companies to pursue more aggressive investment in new molecule development, clinical trials, and advanced pharmaceutical manufacturing. On the US side, the agreement is viewed as a strategic gain aimed at easing the international cost-burden pressures behind elevated drug prices.
Implementation of the agreement could establish a long-term environment of trust in pharmaceutical supply chains between the two nations. However, since drug pricing and patient access remain ongoing political debates in the UK, management of additional financial pressures on the NHS will be closely monitored in the coming period.
Key Points:
The US will maintain zero tariffs on the UK's pharmaceutical exports.
The NHS will pay manufacturers 25 percent more for new medicines.
NHS pharmaceutical spending will increase from 0.3 percent to 0.6 percent of GDP over ten years.
Trump had threatened the UK with 100 percent tariffs.
UK pharmaceutical exports to the US reach 11.1 billion GBP, representing 17 percent of total exports.
Liz Kendall stated the agreement will benefit both patients and pharmaceutical companies.
----------
News Link: https://www.supplychainbrain.com/articles/42917-uk-agrees-to-deal-with-us-to-avoid-drug-tariffs
--------------------
Author: SedatOnat.com
--------------------
!!! ANNOUNCEMENT !!!
How to Procure ERP? Our book has been published on Google Play Books.
#What is ERP?
https://www.sedatonat.com/erpnasilalinir You can download and read it for free via this link.
We would be delighted to receive your feedback.
Wishing you happy reading.